FDA Axes 46 Zombie Drugs: No Sales, No Approval Anymore
Published Date: 3/9/2026
Notice
Summary
The FDA is officially pulling the plug on 46 drug approvals because the companies told them these medicines aren’t being sold anymore. This change kicks in on April 8, 2026, and it affects drugs from Aspen Global Inc. and others. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
46 Drug Approvals Withdrawn April 8, 2026
The FDA withdrew approval of 46 new drug applications (NDAs) as of April 8, 2026 because the applicants told the Agency the products are no longer marketed. If you use any of the listed drugs, those specific approved products are formally no longer approved after April 8, 2026.
Existing Inventory Can Still Be Dispensed
Drug products listed in the notice that are in inventory on April 8, 2026 may continue to be dispensed until those inventories are depleted or the products reach their expiration dates, whichever happens first. This means pharmacies and patients may still get these specific drug products for a limited time after April 8, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20063, Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees
The FDA is looking for smart, qualified people to join its advisory committees and help make important decisions about food and drugs. If you have the right skills, you can apply anytime, but get your nomination in by November 30, 2026, for the best chance at current openings. This is a great chance to influence public health without any cost to you!
Previous / Next Documents
Previous: 2026-04545, Notice of Determinations; Additional Culturally Significant Object Being Imported for Exhibition-Determinations: “Raphael: Sublime Poetry” Exhibition
The U.S. government has approved an extra important artwork to join the “Raphael: Sublime Poetry” exhibition at The Metropolitan Museum of Art in New York. This special piece will be shown temporarily in the U.S. because it’s culturally valuable and benefits the nation. Art lovers and museum visitors can look forward to seeing this new addition soon, with no extra costs to the public.
Next: 2026-04547, Submission for Review: 3206-0194, Annuity Supplement Earnings Report, RI 92-22
If you’re a FERS retiree under 62 who’s not on disability, you might get a special annuity supplement that helps boost your Social Security benefits. The government wants to keep checking your yearly earnings to make sure you still qualify for this extra money. They’re asking for your thoughts on this process until May 8, 2026, so speak up if you have ideas or concerns!